RecruitingNCT05828628

CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study

A Prospective Imaging and Translational Tissue Study in CNS Lymphoma to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers

Sponsor

Royal Marsden NHS Foundation Trust

Enrollment

36 participants

Start Date

Sep 18, 2023

Study Type

OBSERVATIONAL

Conditions

CNS Lymphoma

Summary

A prospective imaging and translational tissue study in CNS lymphoma to enable further disease characterisation and the development of potential predictive and prognostic biomarkers.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting imaging data and biological samples (such as blood and cerebrospinal fluid) from people with primary CNS lymphoma — a rare cancer that affects the brain or spinal cord — to identify better biomarkers that can help diagnose and monitor this disease. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with primary CNS lymphoma (a lymphoma confined to the brain and/or spinal cord) based on imaging or biopsy - You have not yet received any treatment targeting the CNS lymphoma (prior steroid use is allowed) - You or your legal representative can provide informed consent **You may NOT be eligible if...** - Your lymphoma has spread outside the central nervous system (brain/spinal cord) to other parts of the body Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.